{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreid6ed6clfyf5byhr346os2u77rwb3nypknpuodsniup3abkroe5ve",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mhlqh6brvwp2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihl7g4wczznhygy3no7hd3dxuntnphlzfi72pvsbp6z4k4zl2ml4q"
    },
    "mimeType": "image/jpeg",
    "size": 10257
  },
  "path": "/2026/03/21/dizal-announces-positive-topline-phase-3-results-from-wu-kong28-study-evaluating-oral-once-daily-zegfrovy-sunvozertinib-vs-platinum-containing-chemo-doublet-in-first-line-non-small-cell-lun/",
  "publishedAt": "2026-03-21T11:26:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over platinum-containing chemo doublet WU-KONG 28 is the first and only phase 3 study to demonstrate meaningful benefits with an oral, once daily, chemo-free, targeted therapy In addition to improvement in PFS, ZEGFROVY® also showed superior results in all […]",
  "title": "Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)"
}